Phase 1/2 Study of AGN-241622 in Healthy Participants and Participants With Presbyopia

Summary

The objective of this study is to evaluate the safety, tolerability, pharmacokinetics, and efficacy of AGN-241622 ophthalmic solution for the first time in human participants

Timeline

Start

2020-07-27

Primary completion

2022-12-05

Completion

2022-12-05

Outcome

Outcome not reported

Stopped (Business): “Strategic considerations”

Drugs

Indications